About all

Lovenox Interactions: Comprehensive Guide to Uses, Dosage, Side Effects, and Warnings

by alexxlab

What are the major drug interactions with Lovenox. How does Lovenox affect patients with specific medical conditions. What are the essential warnings for Lovenox use. How should Lovenox be dosed and administered safely.

Содержание

Understanding Lovenox: An Overview of the Medication

Lovenox, known generically as enoxaparin, is a widely prescribed anticoagulant medication belonging to the heparin class of drugs. It plays a crucial role in preventing and treating various blood clot-related conditions. As with any potent medication, understanding its interactions, proper usage, and potential side effects is paramount for patient safety and optimal treatment outcomes.

What is Lovenox used for?

Lovenox is primarily used in the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It’s also employed in managing acute coronary syndrome and angina. The medication works by inhibiting specific clotting factors in the blood, thereby reducing the risk of harmful clot formation.

Lovenox Drug Interactions: A Comprehensive Analysis

Drug interactions can significantly impact the effectiveness and safety of Lovenox. According to the data provided, there are 192 known drug interactions with Lovenox. These interactions are categorized based on their severity:

  • 94 major interactions
  • 92 moderate interactions
  • 6 minor interactions

Understanding these interactions is crucial for healthcare providers and patients alike. Let’s delve deeper into some of the most frequently checked interactions.

Major Drug Interactions with Lovenox

Major interactions pose the highest risk and often require avoiding the combination or close monitoring. Some notable major interactions include:

  • Warfarin (Coumadin): Combining Lovenox with warfarin can significantly increase the risk of bleeding.
  • Aspirin: Concurrent use may enhance anticoagulant effects, potentially leading to excessive bleeding.
  • Clopidogrel: This antiplatelet medication can increase the risk of bleeding when used with Lovenox.

Moderate Drug Interactions

Moderate interactions may require dose adjustments or close monitoring. Examples include:

  • NSAIDs (e.g., ibuprofen): These can increase the risk of gastrointestinal bleeding when used with Lovenox.
  • Selective Serotonin Reuptake Inhibitors (SSRIs): Some antidepressants may enhance the anticoagulant effect of Lovenox.

Lovenox and Specific Medical Conditions: Disease Interactions

Lovenox interacts with 12 specific medical conditions, highlighting the importance of a thorough patient history before prescribing. These disease interactions include:

  1. Hemophilia
  2. Liver disease
  3. Peptic ulcer disease
  4. Retinopathy
  5. Subacute bacterial endocarditis
  6. Active bleeding
  7. Hypertension
  8. Renal dysfunction
  9. Thrombocytopenia
  10. Prematurity
  11. Kidney disease

Each of these conditions may affect how Lovenox works in the body or increase the risk of side effects. For instance, patients with liver or kidney disease may require dose adjustments due to altered drug metabolism and excretion.

Lovenox Dosage and Administration: Ensuring Safe and Effective Use

Proper dosing of Lovenox is critical for its safety and efficacy. The dosage varies depending on the condition being treated and individual patient factors.

How is Lovenox typically administered?

Lovenox is usually administered as a subcutaneous injection. The specific dosage and frequency depend on the condition being treated, the patient’s weight, and other medical factors. It’s crucial that patients or caregivers are properly trained in the administration technique to ensure safe and effective use.

Dosage considerations for specific conditions

  • DVT prophylaxis: Typically 40 mg once daily
  • Acute DVT treatment: Usually 1 mg/kg twice daily
  • Acute coronary syndrome: Dosing may vary based on specific patient factors and treatment protocols

It’s important to note that these are general guidelines, and actual dosing should always be determined by a healthcare provider based on individual patient needs and risk factors.

Side Effects of Lovenox: What Patients Should Know

While Lovenox is generally well-tolerated, it can cause side effects ranging from mild to severe. Understanding these potential effects is crucial for patients and healthcare providers.

Common side effects of Lovenox

  • Bleeding or bruising at the injection site
  • Mild pain or irritation at the injection site
  • Fever
  • Nausea
  • Confusion

Serious side effects requiring immediate medical attention

  • Unusual bleeding or bruising
  • Signs of internal bleeding (e.g., blood in urine or stools)
  • Severe headache or dizziness
  • Unusual fatigue or weakness
  • Signs of allergic reaction (e.g., rash, itching, swelling)

Patients should be educated about these potential side effects and instructed to report any concerning symptoms to their healthcare provider promptly.

Critical Warnings for Lovenox Use: Spinal/Epidural Hematoma Risk

One of the most critical warnings associated with Lovenox use pertains to the risk of spinal or epidural hematoma, particularly in patients undergoing spinal procedures.

Why is the risk of spinal/epidural hematoma significant?

Bleeding near the spinal cord can lead to severe complications, including long-lasting or permanent paralysis. This risk is particularly heightened in patients undergoing spinal procedures while on Lovenox therapy.

Factors that increase the risk of spinal/epidural hematoma

  • Spinal deformities
  • History of spinal surgery or difficult spinal/epidural punctures
  • Concurrent use of other medications that affect blood clotting

Healthcare providers must carefully weigh the benefits and risks before any spinal procedure in patients on Lovenox. Specific timing guidelines for stopping and restarting Lovenox around these procedures should be strictly followed.

Lovenox in Special Populations: Pregnancy, Breastfeeding, and Elderly

The use of Lovenox in special populations requires careful consideration and often specialized management.

Lovenox during pregnancy

Lovenox is often considered safer than some other anticoagulants during pregnancy, as it doesn’t cross the placenta. However, its use should still be carefully monitored and prescribed only when the potential benefits outweigh the risks.

Breastfeeding considerations

Limited data suggest that Lovenox may be compatible with breastfeeding, as minimal amounts are excreted in breast milk. However, each case should be evaluated individually, weighing the benefits of breastfeeding against potential risks.

Use in elderly patients

Elderly patients may be at increased risk of bleeding complications with Lovenox. Dose adjustments may be necessary, particularly in those with reduced kidney function, which is common in older adults.

Monitoring and Managing Lovenox Therapy: Best Practices

Effective management of Lovenox therapy involves regular monitoring and adherence to best practices to ensure safety and efficacy.

What laboratory tests are used to monitor Lovenox therapy?

Unlike traditional heparin, Lovenox doesn’t require routine coagulation monitoring in most cases. However, anti-Factor Xa levels may be measured in certain situations, such as in patients with severe renal impairment or extreme body weights.

Best practices for Lovenox management

  • Regular assessment of bleeding risk
  • Monitoring for signs of thrombocytopenia
  • Educating patients on proper injection technique and potential side effects
  • Ensuring appropriate dosing based on indication and patient factors
  • Coordinating care with other healthcare providers, especially before surgical procedures

Adherence to these practices can significantly improve patient outcomes and reduce the risk of complications associated with Lovenox therapy.

Alternatives to Lovenox: Comparing Treatment Options

While Lovenox is a widely used and effective anticoagulant, there are situations where alternative treatments may be considered. Understanding these options can help healthcare providers make informed decisions based on individual patient needs.

What are some alternatives to Lovenox?

  • Unfractionated heparin: Often used in hospital settings, especially for patients with severe renal impairment
  • Direct oral anticoagulants (DOACs): Such as rivaroxaban, apixaban, or dabigatran, which offer convenient oral dosing
  • Warfarin: A long-standing oral anticoagulant, though requiring more frequent monitoring
  • Fondaparinux: Another subcutaneous anticoagulant with a different mechanism of action

Factors to consider when choosing between Lovenox and alternatives

The choice between Lovenox and other anticoagulants depends on various factors, including:

  • The specific condition being treated
  • Patient’s renal function
  • Risk of bleeding
  • Need for reversal in emergency situations
  • Patient preference and ability to adhere to treatment regimen
  • Cost and insurance coverage

Healthcare providers should carefully weigh these factors when deciding on the most appropriate anticoagulant therapy for each patient.

Patient Education: Empowering Safe Use of Lovenox

Educating patients about Lovenox is crucial for ensuring safe and effective use of the medication. Proper patient education can significantly improve adherence and reduce the risk of complications.

Key points for patient education

  1. Proper injection technique: Patients should be thoroughly instructed on how to administer Lovenox subcutaneously, including proper site rotation and disposal of needles.
  2. Recognizing signs of bleeding: Patients should be aware of signs of excessive bleeding or bruising and know when to seek medical attention.
  3. Importance of adherence: Emphasize the need to take Lovenox exactly as prescribed, without missing doses or stopping the medication without consulting their healthcare provider.
  4. Lifestyle considerations: Discuss any necessary precautions regarding activities or diet while on Lovenox therapy.
  5. Interaction awareness: Educate patients about potential drug interactions and the importance of informing all healthcare providers about their Lovenox use.

Tools for patient education

Healthcare providers can utilize various tools to enhance patient education, including:

  • Written materials with clear, easy-to-understand instructions
  • Video demonstrations of proper injection technique
  • Hands-on training sessions with healthcare professionals
  • Follow-up phone calls or appointments to address questions or concerns
  • Mobile apps or online resources for ongoing support and information

Effective patient education not only improves safety but also empowers patients to take an active role in their treatment, potentially leading to better overall outcomes.

Future Directions in Anticoagulation Therapy: Beyond Lovenox

As medical science advances, new developments in anticoagulation therapy continue to emerge. Understanding these trends can provide insight into the future landscape of treatments for thrombotic disorders.

Emerging therapies and research directions

  • Novel oral anticoagulants with improved safety profiles
  • Targeted therapies that focus on specific coagulation factors
  • Gene therapy approaches to address inherited thrombophilias
  • Development of reversal agents for newer anticoagulants
  • Personalized medicine approaches using genetic testing to optimize anticoagulation therapy

Potential impact on current treatment paradigms

These advancements could potentially lead to:

  • More tailored anticoagulation strategies based on individual patient characteristics
  • Reduced need for frequent monitoring and dose adjustments
  • Improved safety profiles with lower risks of bleeding complications
  • Enhanced quality of life for patients requiring long-term anticoagulation

While Lovenox remains a cornerstone of anticoagulation therapy, ongoing research promises to expand the arsenal of treatment options available to clinicians and patients alike.

Conclusion: Navigating the Complexities of Lovenox Therapy

Lovenox (enoxaparin) plays a vital role in the prevention and treatment of thromboembolic disorders. Its efficacy in managing conditions such as deep vein thrombosis, pulmonary embolism, and acute coronary syndrome is well-established. However, the complexity of its interactions, dosing requirements, and potential side effects necessitates a thorough understanding by healthcare providers and careful management for each patient.

Key takeaways from this comprehensive review include:

  • The importance of recognizing and managing drug interactions, with 192 known interactions ranging from major to minor
  • The critical need to consider disease interactions, particularly in patients with conditions such as renal dysfunction or active bleeding
  • The significance of proper dosing and administration, tailored to each patient’s specific condition and risk factors
  • The crucial role of patient education in ensuring safe and effective use of Lovenox
  • The ongoing need for vigilance regarding potential side effects, especially the risk of bleeding complications

As medical science continues to advance, new anticoagulation therapies and treatment strategies are likely to emerge. However, Lovenox remains a crucial tool in the management of thrombotic disorders. By maintaining a comprehensive understanding of its use, interactions, and potential complications, healthcare providers can optimize patient outcomes and minimize risks associated with anticoagulation therapy.

Ultimately, the safe and effective use of Lovenox requires a collaborative approach involving healthcare providers, patients, and ongoing research efforts. This comprehensive approach ensures that patients receive the best possible care while managing the complexities associated with anticoagulation therapy.

Lovenox Interactions Checker – Drugs.com

Print

Save

There are 192 drugs known to interact with
Lovenox (enoxaparin), along with
12 disease interactions, and 2 alcohol/food interactions.

Of the total drug interactions,
94 are major, 92 are moderate, and 6 are minor.

Does Lovenox interact with my other drugs?

Enter other medications to view a detailed report.

  • View all 192 medications that may interact with Lovenox
  • View Lovenox alcohol/food interactions (2)
  • View Lovenox disease interactions (12)

Most frequently checked interactions

View interaction reports for Lovenox (enoxaparin) and the medicines listed below.

  • Major
  • Moderate
  • Minor
  • Unknown
  • albuterol
  • amlodipine
  • aspirin
  • Colace (docusate)
  • Coumadin (warfarin)
  • Fish Oil (omega-3 polyunsaturated fatty acids)
  • furosemide
  • gabapentin
  • hydrochlorothiazide
  • Lasix (furosemide)
  • levothyroxine
  • Lipitor (atorvastatin)
  • lisinopril
  • losartan
  • metformin
  • metoprolol
  • multivitamin
  • omeprazole
  • oxycodone
  • potassium chloride
  • prednisone
  • Protonix (pantoprazole)
  • simvastatin
  • Synthroid (levothyroxine)
  • tramadol
  • Tylenol (acetaminophen)
  • Vitamin C (ascorbic acid)
  • Vitamin D3 (cholecalciferol)
  • warfarin
  • Zofran (ondansetron)

Lovenox alcohol/food interactions

There are 2 alcohol/food interactions with Lovenox (enoxaparin).

Lovenox disease interactions

There are 12 disease interactions with Lovenox (enoxaparin) which include:

  • hemophilia
  • liver disease
  • peptic ulcer disease
  • retinopathy
  • subacute bacterial endocarditis
  • active bleeding
  • hypertension
  • renal dysfunction
  • thrombocytopenia
  • prematurity
  • hypertension
  • kidney disease

Report options

Loading…

QR code containing a link to this page

More about Lovenox (enoxaparin)

  • Lovenox consumer information
  • Compare alternatives
  • Pricing & coupons
  • Reviews (20)
  • Latest FDA alerts (5)
  • Side effects
  • Dosage information
  • During pregnancy
  • Generic availability
  • Support group
  • Drug class: heparins
  • Breastfeeding
  • En español

Related treatment guides

  • Acute Coronary Syndrome
  • Angina
  • Deep Vein Thrombosis
  • Deep Vein Thrombosis Prophylaxis after Abdominal Surgery

Drug Interaction Classification
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
MajorHighly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
ModerateModerately clinically significant. Usually avoid combinations; use it only under special circumstances.
MinorMinimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
UnknownNo interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Lovenox Subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Warnings:

People using this medication may bleed near the spinal cord after certain spinal procedures. Bleeding in this area can cause paralysis that lasts a long time or could become permanent. Talk with your doctor about the benefits and risks before any spinal procedure. Your doctor may direct you to stop this medication for a certain amount of time before and after the procedure. Carefully follow your doctor’s directions.

The risk of bleeding may be higher if you have a deformed spine, or have had spinal procedures/surgery before (such as epidural catheter placement, difficult epidural/spinal puncture), or are taking other drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, “blood thinners” such as warfarin/rivaroxaban, nonsteroidal anti-inflammatory drugs-NSAIDs such as ibuprofen). Tell your doctor right away if you notice symptoms such as back pain, leg numbness/tingling/weakness, loss of control of the bowels or bladder (incontinence).

Warnings:

People using this medication may bleed near the spinal cord after certain spinal procedures. Bleeding in this area can cause paralysis that lasts a long time or could become permanent. Talk with your doctor about the benefits and risks before any spinal procedure. Your doctor may direct you to stop this medication for a certain amount of time before and after the procedure. Carefully follow your doctor’s directions.

The risk of bleeding may be higher if you have a deformed spine, or have had spinal procedures/surgery before (such as epidural catheter placement, difficult epidural/spinal puncture), or are taking other drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, “blood thinners” such as warfarin/rivaroxaban, nonsteroidal anti-inflammatory drugs-NSAIDs such as ibuprofen). Tell your doctor right away if you notice symptoms such as back pain, leg numbness/tingling/weakness, loss of control of the bowels or bladder (incontinence).

… Show More

Uses

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a “blood thinner.” It is a type of heparin.Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other “blood thinners.

How to use Lovenox Syringe

Read the Patient Information Leaflet if available from your pharmacist before you start using enoxaparin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is given by injection under the skin as directed by your doctor, usually once or twice a day in the abdomen (at least 2 inches from your belly button). Do not inject into a muscle. The dosage and length of treatment are based on your medical condition and response to treatment. The dosage may also be based on your age and weight for some conditions. Use this medication regularly to get the most benefit from it. To help you remember, use it at the same time(s) each day.

If you are using this medication at home, learn all preparation and usage instructions from your health care professional and the product package. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Before injecting each dose, clean the injection site with rubbing alcohol. Change the injection site each time to lessen injury under the skin. To minimize bruising, do not rub the injection site after a shot. Learn how to store and discard medical supplies safely.

This medication may also be given by injection into a vein by a health care professional, as directed by your doctor.

Side Effects

See also Warning section.

Mild irritation, pain, bruising, redness, and swelling at the injection site may occur. Fatigue or fever may also occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

This medication can cause bleeding if its effect on your blood clotting proteins is too much. Tell your doctor right away if you have any serious signs of bleeding, including: unusual pain/swelling/discomfort, unusual or prolonged bleeding, unusual or easy bruising, dark urine, black stools, severe headache, confusion, vision changes, unusual dizziness, fainting, seizures, weakness, numbness.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before using enoxaparin, tell your doctor or pharmacist if you are allergic to it; or to heparin or pork products; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using enoxaparin, tell your doctor or pharmacist your medical history, especially of: artificial heart valve(s), kidney disease, liver disease, bleeding/blood problems (such as low platelet counts), low platelet counts after previous heparin treatment, stroke, high blood pressure, certain eye problems (such as diabetic retinopathy), certain stomach/intestinal problems (such as active or recent ulcers), recent spinal procedure or puncture, spine problems (such as spinal deformity), recent eye/brain/spinal cord surgery.

Limit alcohol while taking this drug because it may increase the risk of stomach bleeding.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports.

Older adults may be more sensitive to the side effects of this drug, especially bleeding.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.

A product that may interact with this drug is: mifepristone.

This medication is sometimes used together with other drugs that have “blood thinning” or anti-platelet effects such as aspirin, clopidogrel, or warfarin. When these combinations are prescribed by your doctor, you will require closer monitoring to minimize your risk of bleeding. Keep all medical and lab appointments.

Check all prescription and nonprescription medicine labels carefully since many medications contain pain relievers/fever reducers (NSAIDs such as ibuprofen, naproxen, or aspirin) which can increase the risk of bleeding/anti-platelet effect when used with enoxaparin. However, if your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually 81-162 milligrams a day), you should continue taking it unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.

Does Lovenox Syringe interact with other drugs you are taking?

Enter your medication into the WebMD interaction checker

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: excessive bleeding and bruising.

Do not share this medication with others.

Lab and/or medical tests (such as complete blood count, anti-factor Xa blood levels) should be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details.

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.

Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not store the multiple dose vials for more than 28 days after the first use.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Images

Lovenox 120 mg/0.8 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 30 mg/0.3 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 80 mg/0.8 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 60 mg/0.6 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 40 mg/0.4 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 300 mg/3 mL subcutaneous solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 100 mg/mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 150 mg/mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Next

Save up to 80% on your prescriptions.

Available coupons

Save up to 80% on your prescription with WebMDRx

Drug Survey

Are you currently using Lovenox Syringe?

This survey is being conducted by the WebMD marketing sciences department.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Today on WebMD

Lovenox Injectable – Product

Lovenox Injectable – Product – TabletWise.com

About us

  • 008
  • Terms of use

  • Overview
  • Benefits
  • Side effects
  • Precautions
  • Interactions
  • Contraindications

Overview

Lovenox Injectable / Lovenox Injectable is indicated for the treatment of deep vein thrombosis, Ischemic complications of unstable chest pain, Acute deep vein thrombosis, Non-q-wave myocardial infarction, Acute st-segment elevation myocardial infarction and other conditions .

Lovenox Injectable contains the following active ingredients: Enoxaparin Sodium. Available in injectable form.

Detailed information regarding the use, composition, dosage, side effects of Lovenox Injectable / Lovenox Injectable, as well as user reviews are provided below:

Uses

Lovenox Injectable is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:

  • Deep vein thrombosis
  • Ischemic complications of unstable chest pain
  • Acute deep vein thrombosis 90 008
  • Numbers q -wave myocardial infarction
  • Acute st-segment height myocardial infarction

Learn more: Use

Side effects

The following is a list of possible side effects that may be caused by the ingredients of Lovenox Injectable. This list is not final. These side effects have been recorded previously, but are not always recorded when using the drug. Some of these side effects may be extremely rare, but have incredibly severe consequences. If you notice any side effects, contact your doctor immediately. Especially in the case of observing side effects for a long time.

  • Dyspnea
  • Hemorrhage
  • Irritation
  • Pain
  • Hematoma
  • Anemia
  • Ecchymosis

    • 900 06 Fever

  • Nausea
  • Dropsy
  • Dyspnea
  • Thrombocytopenia
  • Confusion
  • Diarrhea
  • Hematuria

    • 90 015

    If If you experience side effects not listed above, contact your healthcare provider for advice. In addition, you can report side effects to your local Food and Drug Administration.

    Precautions

    Before starting this drug, tell your doctor about any medications you are taking, nutritional supplements (such as vitamins, natural supplements, etc. ), allergies, existing medical conditions, and current health conditions (such as pregnancy, upcoming surgery, and etc.). The side effects of the drug may be more pronounced depending on the state of your body. Take this medicine as directed by your doctor, or follow the directions for use that come with your medicine. The dosage of the drug depends on your condition. Tell your doctor if there is no change or if your condition worsens. Important points to discuss with your healthcare provider are listed below.

    • monitor peak and trough anti-factor Xa levels frequently

    If you use other drugs or supplements at the same time as this drug, the effects of Lovenox Injection may change. Tell your healthcare provider about all medications, vitamins, and supplements you use. Your doctor will be able to make the right plan for taking the drug, which will avoid negative interactions. Lovenox Injectable may interact with the following drugs and products:

    • Acetylsalicylic acid
    • Anticoagulants
    • Dipyridamole
    • Ketorolac tromethamine
    • Salicylates
    • Sulfinpyrazone

      • 900 15

      Hypersensitivity to Lovenox Injectable is a contraindication. In addition, Lovenox Injectable should not be taken if you have the following conditions:

      • active severe bleeding
      • hypersensitivity

        8

      • thrombocytopenia

      Composition and active ingredients

      Lovenox Injectable contains the following active ingredients (salts)

      • Enoxaparin Sodium

      Please note that that this drug is produced with different strengths of intensity for each from the active ingredients listed above.

      Packing Options and Strengths

      Lovenox Injectable is available in the following pack strengths

      Available packages of Lovenox Injectable / Lovenox Injectable: 100MG/ML, 300MG/3ML (100MG/ML)

      FAQ

      • veins and ischemic complications of unstable pain in chest?

        Yes, deep vein thrombosis and ischemic complications of unstable chest pain are among the most common reported uses for Lovenox Injection / Lovenox Injectable. Please do not use Lovenox Injectable for deep vein thrombosis and ischemic complications of unstable chest pain without consulting first with your doctor. Click here and view survey results to find out how others use Lovenox Injection / Lovenox Injectable.

      • Should I use this product on an empty stomach, before or after meals?

        TabletWise.com users have reported taking Lovenox Injectable before meals. However, this information may not apply to your specific situation. Please check with your healthcare provider for a schedule. Click here and view survey results to find out what other users report as timings of using Lovenox Injectable / Lovenox Injectable.

      • Is it safe to drive or operate heavy machinery while using this product?

        If you experience drowsiness, dizziness, hypotension or a headache as side-effects when using Lovenox Injection / Lovenox Injectable medicine then it may not be safe to drive a vehicle or operate heavy machinery. You should stop driving if taking this medicine makes you drowsy, dizzy, or hypotensive. Doctors recommend that you stop drinking alcohol with such drugs, because. alcohol greatly increases the side effects and drowsiness. Please check for these effects on your body when using Lovenox Injectable. Be sure to consult your doctor for advice based on the characteristics of your body and general health.

      • Is this drug (product) addictive or addictive?

        Most drugs are not habit-forming or addictive. In most cases, the state classifies drugs that can be addictive as controlled dispensing drugs. For example, schedule H or X in India and schedule II-V in the USA. Please check the information on the drug packaging to make sure that this drug is not in the controlled category. Also, do not self-medicate or accustom your body to medications without consulting your doctor.

      • Can I stop using this product immediately or do I need to slowly stop using it?

        Some medications need to be stopped gradually due to a rebound effect. Be sure to consult your healthcare provider for advice based on your body, general health, and other medications you may be taking.

      Cite this page

      Page URL

      HTML Link

      Lovenox Injectable

      APA Style Citation
      • Lovenox Injectable jetable in English – Product – TabletWise.com. (n.d.). Retrieved April 14, 2023, from https://www.tabletwise.com/us-ru/lovenox-injectable
      MLA Style Citation
      • “Lovenox Injectable / Lovenox Injectable in English – Product – TabletWise.com” Tabletwise.com . N.p., n.d. Web. 14 Apr. 2023.
      Chicago Style Citation
      • Lovenox Injectable in English – Product – TabletWise.com Tabletwise. Accessed April 14, 2023. https://www.tabletwise.com/us-ru/lovenox-injectable.

      More information about Lovenox Injectable / Lovenox Injectable

      • Uses of
      • Reviews
      • What are the uses of Lovenox Injectable / Lovenox Injectable?
      • What are the side effects of Lovenox Injectable?
      • What other medicines does Lovenox Injectable interact with?
      • When should you not take Lovenox Injectable?
      • What precautions should you take while using Lovenox Injectable?

      Last updated date

      This page was updated on 9/28/2020.

      This page provides information for Lovenox Injectable Product in English .

      Share with friends, get 20% off

      Invite your friends to TabletWise learning marketplace. For each purchase they make, you get 20% off (upto $10) on your next purchase.

      Use of statins, anticoagulants, antiplatelet agents and antiarrhythmic drugs in patients with COVID-19 | Shlyakhto

      1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al. Endothelial cell infection and endothelitis in COVID-19. The Lancet. 2020;395(10234):1417–8. DOI: 10.1016/S0140-6736(20)30937-5

      2. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis. 2020;jth.14849. [Epub ahead of print]. DOI: 10.1111/jth.14849

      3. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1286

      4. Hu T, Chen B, Zhou S, Mao J. Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. International Journal of Clinical and Experimental Pathology. 2018;11(8):3925–33. PMID: 31949780

      5. Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. 2019;8(12):2051. DOI: 10.3390/jcm8122051

      6. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. The Lancet Haematology. 2017;4(2):e83–93. DOI: 10.1016/S2352-3026(16)30184-3

      7. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. European Heart Journal. 2017;38(20):1608–12. DOI: 10.1093/eurheartj/ehx107

      8. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: A potential therapeutic approach to rheumatoid arthritis. Arthritis & Rheumatism. 2006;54(2):579–86. DOI: 10.1002/art.21564

      9. Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015;6(4):e01120. DOI: 10.1128/mBio.01120-15

      10. Fedson DS. Treating influenza with statins and other immunomodulatory agents. antiviral research. 2013;99(3):417–35. DOI: 10.1016/j.antiviral.2013.06.018

      11. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J et al. Association Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate Study. Journal of Infectious Diseases. 2012;205(1):13–9. DOI: 10.1093/infdis/jir695

      12. Massachusetts General Hospital. Hematology Recommendations and Dosing Guidelines during COVID-19. Version 8.0. 4/30/2020. Av. at: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guidance-from-mass-general-hematology.pdf.

      13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. DOI: 10.1001/jama.2020.1585

      14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;e201017. [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1017

      15. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A et al. Clinical Characteristics of Covid-19in New York City. New England Journal of Medicine. 2020;NEJMc2010419. [Epub ahead of print]. DOI: 10.1056/NEJMc2010419

      16. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Av. at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.

      17. The Liverpool Drug Interaction Group. Liverpool COVID-19 Interactions. Detailed recommendations for interactions with experimental COVID-19therapies. 2020. [Internet] Available at: https://www.covid19-druginteractions.org/

      18. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

      19. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. European Heart Journal. 2020;41(19):1798–800. DOI: 10.1093/eurheartj/ehaa231

      20. Kushakovsky M.S., Grishkin Yu.N. Arrhythmias of the heart. Rhythm and conduction disturbances. Causes, mechanisms, electrocardiographic and electrophysiological diagnostics, clinic, treatment: a guide for physicians. 4th ed., rev. and additional – St. Petersburg: Folio, 2014. -720s. ISBN 978-5-93929-245-0

      21. Heart Rhythm Society. HRS COVID-19 Task Force Update: April 21, 2020. General guidance for QTc monitoring in COVID-19 patients. Av. at: https://www.hrsonline.org/hrs-covid-19-task-force-updateapril-21-2020.

      22. Ministry of Health of the Russian Federation. Temporary guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-2019). Version 6 (04/28/2020). Available at: https://ctopcoronavirus.rf/ai/doc/194/attach/28042020_mR_COVID-19_v6.pdf

      23. Shlyakhto E.V., Konradi A.O., Arutyunov G.P., Arutyunov A.G. ., Bautin A.E., Boytsov S.A. et al. Guidance for the diagnosis and treatment of diseases of the circulatory system in the context of the COVID-19 pandemic. Russian journal of cardiology. 2020;25(3):129-48. DOI: 10.15829/1560-4071-2020-3-3801

      24. Arutyunov G.P., Tarlovskaya E.I., Koziolova N.A., Boldina M.V., Batyushin M.M., Ametov A. WITH. Agreed position of experts of the Eurasian Association of Physicians on the tactics of managing patients with comorbid pathology infected with SARS-Cov-2. Therapeutic archive. 2020;92(9). (in the press). DOI: 10.26442/00403660.2020.09.000703

      25. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020;S0735109720350087. [Epub ahead of print]. DOI: 10.1016/j.jacc.2020.04.031

      26. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020;jth.14810. [Epub ahead of print]. DOI: 10.1111/jth.14810

      27. Arutyunov G.P., Koziolova N.A., Tarlovskaya E.I., Arutyunov A.G., Grigoryeva N.Yu., Dzhunusbekova G.A. Agreed position of experts of the Eurasian Association of Physicians on some new mechanisms of the pathogenesis of COVID19: focus on hemostasis, issues of blood transfusion and the blood gas transport system. Cardiology. 2020;60(5):1-8. DOI: 10.18087/cardio.2020.5.n1132

      28. Cohen AT, Spiro TE, Spyropoulos AC, DeSanctis YH, Homering M, Büller HR et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. Journal of Thrombosis and Haemostasis. 2014;12(4):479-87. DOI: 10.1111/jth.12515

      29. Gibson C, Spyropoulos A, Cohen A, Hull R, Goldhaber S, Yusen R et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017;1(1):e56–65. DOI: 10.1055/s-0037-1603929

      30. Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC et al. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. radiology. 2020;201629. [Epub ahead of print]. DOI: 10.1148/radiol.2020201629

      31. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score: Padua Prediction Score. Journal of Thrombosis and Haemostasis. 2010;8(11):2450–7. DOI: 10.1111/j.1538-7836.2010.04044.x

      32. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine. 2013;368(6):513–23. DOI: 10.1056/NEJMoa1111096

      33. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. New England Journal of Medicine. 2011;365(23):2167–77. DOI: 10.1056/NEJMoa1110899

      34. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. 2020;18(5):1094–9. DOI: 10.1111/jth.14817

      35. Iba T, Levy JH, Warkentin TE, Thachil J, Poll T, Levi M et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis. 2019;17(11):1989–94. DOI: 10.1111/jth.14578

      36. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al. Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e195S-e226S. DOI: 10.1378/chest.11-2296

      37. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P et l. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial. Annals of Internal Medicine. 2010;153(1):8. DOI: 10.7326/0003-4819-153-1-201007060-00004

      38. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.